DelveInsight’s “Osteoporosis – Pipeline Insight, 2026” report provides comprehensive insights about 30+ companies developing over 35 pipeline therapies in the clinical and nonclinical development landscape. It covers the Osteoporosis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights commercial activities like collaborations and licensing in this space.
Explore the latest breakthroughs in the Osteoporosis treatment landscape. Learn more about the evolving Osteoporosis pipeline today @ https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Osteoporosis Pipeline Report
-
Nov 15, 2025: Alvotech’s AVT03, a biosimilar candidate targeting the RANK ligand to reduce bone resorption, is currently in Phase III clinical development.
-
Jan 20, 2026: Transcenta Holding is advancing TST002, a Phase II monoclonal antibody designed to stimulate bone formation while inhibiting absorption.
-
Mar 10, 2026: GlycoNex announced that its denosumab biosimilar, SPD8, recently met its primary endpoints in Phase I clinical trials.
-
Osteoporosis is a “silent” bone disease characterized by decreased bone mineral density and mass, often leading to fractures before symptoms appear.
-
DelveInsight’s report highlights a robust clinical development space with 30+ active players advancing 35+ pipeline therapies from discovery through Phase III.
-
Diagnostic methods such as DEXA scans remain critical in identifying the disease early to prevent debilitating fractures.
-
Promising therapies in development include AVT03, TST002, and SPD8, which aim to improve treatment outcomes by effectively stopping bone loss.
-
The leading Osteoporosis companies include Alvotech, Transcenta Holding, GlycoNex, and others involved in targeted therapeutics development.
Download for updates and the latest revolution in Osteoporosis care @ Osteoporosis Market Insight, Epidemiology And Market Forecast
Osteoporosis Emerging Drugs Profile
AVT03: Alvotech
AVT03 is a biosimilar candidate currently in Phase III clinical development. It is designed to target the RANK ligand, a key mediator in bone remodeling, to reduce bone resorption in patients with Osteoporosis. The development of AVT03 reflects Alvotech’s commitment to expanding access to critical biologic therapies for bone health.
TST002: Transcenta Holding
TST002 is a Phase II monoclonal antibody therapy being developed by Transcenta Holding. This innovative candidate is designed with a dual mechanism of action intended to stimulate bone formation while simultaneously inhibiting bone absorption. Currently, TST002 is undergoing evaluation to determine its efficacy in improving treatment outcomes and preventing fractures.
SPD8: GlycoNex
SPD8 is a biosimilar of denosumab developed by GlycoNex. It recently achieved a significant milestone by meeting its primary endpoints in Phase I clinical trials. The therapy aims to provide an effective option for stopping bone loss and managing the “silent” progression of Osteoporosis.
For more information on the Osteoporosis Emerging Drugs Profile, download DelveInsight’s comprehensive Osteoporosis Pipeline Insight report.
The Osteoporosis Pipeline Report Provides
-
Detailed insights about companies developing therapies for Osteoporosis, with aggregate therapies developed by each company.
-
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Osteoporosis treatment.
-
Osteoporosis companies that are involved in targeted therapeutics development with respective active and inactive projects.
-
Drug profiles under development based on stage, route of administration, and molecular type, such as small molecules and peptides.
-
Detailed analysis of commercial activities including collaborations, licensing agreements, and mergers within the osteoporosis sector.
Learn more about Osteoporosis drug opportunities in our comprehensive Osteoporosis pipeline report @ Osteoporosis Unmet Needs
Osteoporosis Companies and Competitive Landscape
There are 30+ key companies, including Alvotech, Transcenta Holding, GlycoNex, and others, developing therapies for Osteoporosis across multiple stages of clinical development. The competitive landscape is characterized by a focus on novel monoclonal antibodies, biosimilars, and small molecules aimed at addressing unmet needs in bone mineral density management.
DelveInsight’s Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Osteoporosis products have been categorized under various Molecule types such as:
-
Oligonucleotide
-
Peptide
-
Small molecule
Discover the latest advancements in Osteoporosis treatment by visiting our website. Stay informed @ Osteoporosis Market Drivers and Barriers, and Future Perspectives
Scope of the Osteoporosis Pipeline Report
-
Coverage: Global
-
Osteoporosis Companies: Alvotech, Transcenta Holding, GlycoNex, and others.
-
Osteoporosis Therapies: AVT03, TST002, SPD8, and other pipeline candidates.
-
Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
-
Osteoporosis drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Osteoporosis market.
Table of Contents
-
Introduction
-
Executive Summary
-
Osteoporosis: Overview
-
Pipeline Therapeutics
-
Therapeutic Assessment
-
Osteoporosis – DelveInsight’s Analytical Perspective
-
Late Stage Products (Phase III)
-
Mid Stage Products (Phase II)
-
Early Stage Products (Phase I)
-
Preclinical and Discovery Stage Products
-
Inactive Products
-
Osteoporosis Key Companies
-
Osteoporosis Key Products
-
Osteoporosis Unmet Needs
-
Osteoporosis Market Drivers and Barriers
-
Osteoporosis Future Perspectives and Conclusion
-
Osteoporosis Analyst Views
-
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services